Rxpedite, an alliance between inChord Communications and Cardinal Health, has announced an agreement with Acorda Therapeutics to manage the commercialization of Fampridine-SR, a product candidate in development for treatment of spinal cord injury (SCI) and multiple sclerosis (MS).
Rxpedite provides comprehensive sales and marketing solutions to pharmaceutical and biotechnology clients that do not have the internal resources to manage the commercialization process on their own. Through Rxpedite, clients can access customized services ranging from marketing planning, development and implementation; through product manufacturing; packaging and distribution; and sales force deployment.
"We are delighted to work with Acorda to put Rxpedite's resources behind the potential launch of Fampridine-SR," said Dan Twibell, executive vice president of CHS, a company of inChord.
Rxpedite will be helping Acorda develop and implement a plan to launch Fampridine-SR, which is currently in Phase 3 clinical trials. In the event Acorda receives FDA approval to commercialize Fampridine-SR, Cardinal Health will provide sales force deployment, medical education, publication planning, product warehousing, distribution and technical support. inChord will provide marketing strategy and implementation through CHS, its contract marketing organization; professional and consumer advertising through Palio Communications, its full-spectrum advertising agency; Web marketing and promotion through Blue Diesel, its interactive company; data analysis through Health Process Management, its data analytics company; and product branding through Y, its strategic branding company.